HOME » News & Media

    Vyome Biosciences’ IND application receives US FDA approval


    14th Jan 2016. Bio-pharmaceutical company Vyome Biosciences today said the US Food and Drug Administration (USFDA) has cleared its investigational new drug (IND) to treat moderate-to-severe acne. "We have received USFDA acceptance of Investigational New Drug application in the US for our lead product VB-1953 to treat moderate-to-severe acne. We plan to start Phase-I clinical trials very soon," a company statement said here.

    "With accepting our first IND application for the lead program VB-1953, we have become a clinical stage company in US, which is an important value inflection milestone for us. 

    "This should pave way for further filings with the USFDA in future. VB-1953 is a first-in-class new product in Acne therapy for addressing one of the very important and a large unmet need," Vyome CEO N Venkat said.

    Visit: www.vyome.in
    Copyright © 2021 Vyome Biosciences Private Limited.

    Copyright © 2015 Vyome Therapeutics Inc. All rights reserved.